Neurogene Inc. Payments to Acquire Debt Securities, Available-for-sale
Neurogene Inc. (NGNE) reported Payments to Acquire Debt Securities, Available-for-sale of $91.88 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2023-11-14
- Neurogene Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2023-09-30 was $36.61M, a 13.91% decline year-over-year.
- Neurogene Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2023-06-30 was $26.89M, a 31.16% decline year-over-year.
- Neurogene Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2023-03-31 was $28.38M.
- Neurogene Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2022-12-31 was $25.93M.
- Neurogene Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $107.52M.
- Neurogene Inc. payments to acquire debt securities, available-for-sale for fiscal 2021 was $0.00.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2023-09-30 | $36.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $63.51M derived: sum of 2 quarters · filed 2023-11-14 | $91.88M 10-Q · filed 2023-11-14 | $117.81M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | $26.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $55.27M 10-Q · filed 2023-08-10 | $81.20M derived: sum of 3 quarters · filed 2023-08-10 | $123.73M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-03-31 | $28.38M 10-Q · filed 2023-05-08 | $54.30M derived: sum of 2 quarters · filed 2023-05-08 | $96.83M derived: sum of 3 quarters · filed 2023-11-14 | $135.90M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-12-31 | $25.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $68.46M derived: sum of 2 quarters · filed 2023-11-14 | $107.52M derived: sum of 3 quarters · filed 2023-11-14 | $107.52M 10-K · filed 2023-03-20 |
| 2022-09-30 | $42.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $81.59M derived: sum of 2 quarters · filed 2023-11-14 | $81.59M 10-Q · filed 2023-11-14 | $81.59M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $39.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $39.07M 10-Q · filed 2023-08-10 | $39.07M derived: sum of 3 quarters · filed 2023-08-10 | $39.07M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-08 | $0.00 derived: sum of 2 quarters · filed 2023-05-08 | $0.00 derived: sum of 3 quarters · filed 2023-05-08 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $0.00 derived: sum of 2 quarters · filed 2023-03-20 | $0.00 10-K · filed 2023-03-20 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |